Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

Yes, the primary efficacy endpoint is simply lesion size decreased by >20% after 48-72 hours. However, it is critically important that the brilacidin early response compares favorably to daptomycin early response. And it does. With no rescue antibiotics administered for the study groups it's kind of a no brainer.

In a previous post I mistakenly questioned the number of patients that needed rescue- it's clearly stated in the Oct. 23 PR that no rescue antibiotics were administered.